• Patanjali issues unconditional apology to SC for "misleading" advertisements

    National
    Patanjali issues unconditional apology to SC for "misleading" advertisements
    Earlier on February 27, at a Supreme Court hearing, Patanjali Ayurved was prohibited from promoting medications with misleading claims...

    Digital Desk: In response to misleading advertisements and criticism of modern medicine, Patanjali Ayurved has sent an "unconditional apology" to the Supreme Court. This follows the top court's Tuesday, March 19, order for Patanjali Ayurved, which is controlled by Ramdev, and its managing director, Acharya Balakrishna, to personally appear before it to explain why they neglected to reply to the contempt notice and why they ran false advertisements regarding medical remedies.

    The affidavit contained an apology stating: “The Deponent on behalf of Respondent No. 5 submits an unqualified apology before this Hon'ble Court for the breach of the statement recorded in the order of November 21, 2023."

    It further added, "The Deponent will ensure that such advertisements are not issued in the future. By way of clarification, not as a defense, the Deponent begs to submit that its intention is only to exhort the citizens of this country to lead a healthier life by consuming products of the Respondent No. 5 including products for lifestyle ailments through the use age old literature and materials supplementing and backed by ayurvedic research."

    Earlier on February 27, at a Supreme Court hearing, Patanjali Ayurved was prohibited from promoting medications with "misleading claims." The Bench also criticized the Center harshly for "sitting with eyes closed" and "taking the entire country for a ride." 

    Baba Ramdev, the founder of Patanjali Ayurveda, and MD Acharya Balkrishna were served with a contempt of court notice by the Supreme Court for disobeying earlier rulings and persisting in making false statements.

    Last year, on November 21, 2023, the counsel representing the company had assured the court that "henceforth there shall not be any violation of any law(s), especially relating to advertising or branding of products manufactured and marketed by it and, further, that no casual statements claiming medicinal efficacy or against any system of medicine will be released to the media in any form".